January 7, 2021 11:21 AM ESTUpdated January 8, 03:34 PM
News Briefing

News brief­ing: Pfiz­er kick­starts PhI­II tri­al for DMD gene ther­a­py, out­rac­ing Sarep­ta; Teva's re­for­mu­lat­ed schiz­o­phre­nia shot touts win in late-stage study

Kyle Blankenship

Max Gelman

Senior Editor

Conner Mitchell

In the race to bring the first gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy in­to a Phase III tri­al, Pfiz­er has come out on top over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times